New Product: Quviviq (daridorexant) film-coated tablets

Daridorexant is licensed for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.

SPS commentary:

NICE TA922 recommends daridorexant for insomnia in adults with symptoms lasting for 3 nights or more per week for at least 3 months, and whose daytime functioning is considerably affected, only if:

  • cognitive behavioural therapy for insomnia (CBTi) has been tried but not worked, or
  • CBTi is not available or is unsuitable.

It notes that the length of treatment should be as short as possible, and should be assessed within 3 months of starting and should be stopped in people whose long-term insomnia has not responded adequately. If treatment is continued, it should be assessed whether it is still working at regular intervals.

electronic Medicines compendium

Resource links:

NICE TA922